5. Juli 2024 – The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended ten new medicines for approval, including notable treatments for urothelial carcinoma, emergency allergic reactions, and respiratory diseases in older adults. The CHMP issued negative opinions for two medicines and decided not to renew the conditional authorisation for a Duchenne muscular dystrophy treatment. Additionally, the CHMP updated the COVID-19 vaccine Comirnaty to target the new SARS-CoV-2 JN.1 variant.

For more information, see here.